Novel N-pyrimidin-4-yl-3-amino-pyrrolo [3, 4-C] pyrazole derivatives as PKC kinase inhibitors: a patent evaluation of US2015099743 (A1)

C1 Domains: Structure and Ligand-Binding Properties

(2014) Joydip Das et al.   CHEMICAL REVIEWS

Protein kinase C inhibitors: a patent review (2008 – 2009)

(2013) M Elizabeth Sobhia et al.   EXPERT OPINION ON THERAPEUTIC PATENTS

Protein kinase C inhibitors: a patent review (2010 – present)

(2013) Masilamani Elizabeth Sobhia et al.   EXPERT OPINION ON THERAPEUTIC PATENTS

Protein kinase C, an elusive therapeutic target?

(2012) Daria Mochly-Rosen et al.   NATURE REVIEWS DRUG DISCOVERY

Crystal Structure and Allosteric Activation of Protein Kinase C βII

(2011) Thomas A. Leonard et al.   CELL

A Gynecologic Oncology Group phase II trial of the protein kinase C-beta inhibitor, enzastaurin and evaluation of markers with potential predictive and prognostic value in persistent or recurrent epithelial ovarian and primary peritoneal malignancies

(2011) Lydia Usha et al.   GYNECOLOGIC ONCOLOGY

Discovery of a novel class of targeted kinase inhibitors that blocks protein kinase C signaling and ameliorates retinal vascular leakage in a diabetic rat model

(2009) Stephan Grant et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Ruboxistaurin: PKC-β inhibition for complications of diabetes

(2009) Ronald P Danis et al.   EXPERT OPINION ON PHARMACOTHERAPY

A phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory mantle cell lymphoma

(2007) F. Morschhauser et al.   ANNALS OF ONCOLOGY